Infinity Pharmaceuticals Inc (INFI.OQ)
14 Mar 2014
|Market Cap (Mil.):||$653.72|
|Shares Outstanding (Mil.):||48.28|
NEW YORK, Dec 9 - Infinity Pharmaceuticals Inc : * Pharma up 13 percent to $16.90 in premarket after updated IPI-145 data
- Infinity Pharmaceuticals Inc said its cancer drug failed to improve overall survival in a mid-stage study on patients with non-small cell lung cancer who had a history of smoking.
Sept 25 - Infinity Pharmaceuticals Inc said its cancer drug failed to improve overall survival in a mid-stage study on patients with non-small cell lung cancer who had a history of smoking.
|DAIICHI SANKYO COMPANY, LIMITED (4568.T)||¥1,679||-57.00|
|Kyowa Hakko Kirin Co Ltd (4151.T)||¥1,023||-45.00|
|Pfizer Inc. (PFE.N)||$31.23||+0.11|
|Novartis AG (NOVN.VX)||CHF71.20||-0.70|
|Roche Holding Ltd. (ROG.VX)||CHF253.90||-0.40|
|AbbVie Inc (ABBV.N)||$51.21||-0.11|
|Bristol-Myers Squibb Co (BMY.N)||$54.00||-0.18|
|Bristol-Myers Squibb Co (BMYMP.PK)||$937.49||-33.31|
|Amgen, Inc. (AMGN.OQ)||$122.54||-1.40|
|Gilead Sciences, Inc. (GILD.OQ)||$75.05||-2.96|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: Pechala's Reports
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of INFINITY PHARMACEUTICALS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: S&P Capital IQ Quantitative Report
Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.